Journal
CANCER CELL
Volume 29, Issue 4, Pages 429-431Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2016.03.020
Keywords
-
Categories
Ask authors/readers for more resources
AKT inhibitors represent promising therapeutics for cancers with PI3K-AKT pathway hyperactivation. In this issue of Cancer Cell, Wang et al. (2016) report the unexpected finding that ablation of AKT signaling in hepatocytes leads to hepatocellular carcinoma and enhances the incidence of lung metastases in a toxin-induced liver cancer model.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available